1. Amgen buying drug discovery biotech Nuevolution for $167M — Novartis’ asthma drug beats GSK’s Advair in trial — Lilly’s mirikizumab succeeds in phase 2 Crohn’s trial -- See more on our front page news

    Got questions about whistleblowing?: Ask a Whistleblower Attorney
    Dismiss Notice
  2. Dealing with a potential legal issue at work?Ask an Employment Attorney -- a chance to discuss employment-related legal issues with a practicing attorney with over 20 years in employment law experience.
    Dismiss Notice

Roche, Bayer unveil brain tumor data for NTRK inhibitors ahead of ASCO

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, May 17, 2019 at 10:22 AM.

  1. cafead

    cafead Administrator
    Staff Member

    Nov 21, 2001
    Likes Received:
    via Efficacy data for two tissue-agnostic NTRK inhibitors from Roche and Bayer to treat primary and metastatic brain tumors were released in abstracts ahead of the American Society of Clinical Oncology meeting in Chicago.

    Data from the Phase I/II STARTRK-NG trial of entrectinib from Roche (SIX:ROG; OTCQX:RHHBY) showed that the inhibitor of ROS1, TrkA, TrkB, TrkC and ALK led to one complete response (CR), three partial responses (PRs) and one unconfirmed PR among five evaluable pediatric patients with primary CNS tumors.

    article source